In this phase 2 dose-finding study, we evaluated the safety and efficacy of oral infigratinib in children with achondroplasia between the ages of 3 and 11 years. A total of 72 children were ...
This year, we will shed light on achondroplasia, a genetic bone disorder causing short limbs and disproportionate short stature of a person. Read on ahead to know more about the condition and how ...
Discover top medications for 'treating Achondroplasia'? This page compiles essential information on generic and brand-name drugs specifically used for Achondroplasia treatment.Here, you can ...
Opens in a new tab or window The oral FGFR1-3 selective tyrosine kinase inhibitor infigratinib was found to be safe and effective at the highest studied dose among children with achondroplasia in ...
The drug has demonstrated clinical POC in exudative age-related macular degeneration. ABOUT Achondroplasia Achondroplasia is disease in which a genetic mutation of the fibroblast growth factor ...